Jounce Therapeutics, Inc. News Releases http://ir.jouncetx.com/ Jounce Therapeutics, Inc. News Releases en Jounce Therapeutics Reports First Quarter 2019 Financial Results http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-reports-first-quarter-2019-financial-results - New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass. Wed, 08 May 2019 06:30:00 -0400 Jounce Therapeutics, Inc. News Releases 7396 Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019 http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-announce-first-quarter-2019-financial CAMBRIDGE, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report first quarter 2019 financial results and Wed, 01 May 2019 08:00:00 -0400 Jounce Therapeutics, Inc. News Releases 7391 Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-presents-preclinical-data-jtx-8064-program Preclinical data supports the development of JTX-8064 as a novel immunotherapy to reprogram immune-suppressive macrophages and enhance anti-tumor immunity CAMBRIDGE, Mass. , April 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the Wed, 03 Apr 2019 08:02:00 -0400 Jounce Therapeutics, Inc. News Releases 7361 Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-reports-improved-pfs-and-os-associated - Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells - - ICOS hi CD4 T cells demonstrate distinct, activated T effector cell characteristics - - Company to Host Investor Event and Live Webcast on Tue, 02 Apr 2019 13:02:00 -0400 Jounce Therapeutics, Inc. News Releases 7356 Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-reports-fourth-quarter-and-full-year-2018 - New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with ipilimumab and with pembrolizumab - - Ended 2018 with $195.9 million in cash, cash equivalents and Wed, 06 Mar 2019 06:30:00 -0500 Jounce Therapeutics, Inc. News Releases 7326 Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-present-cowen-and-company-39th-annual-health CAMBRIDGE, Mass. , March 04, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray , Ph.D., chief executive officer and Mon, 04 Mar 2019 08:00:00 -0500 Jounce Therapeutics, Inc. News Releases 7321 Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019 http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-announce-fourth-quarter-and-full-year-2018 CAMBRIDGE, Mass. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2018 financial Thu, 28 Feb 2019 08:00:00 -0500 Jounce Therapeutics, Inc. News Releases 7311 Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-present-data-its-jtx-2011-and-jtx-8064 ICONIC Clinical Data Demonstrates Improved PFS/OS in Patients with Emergence of JTX-2011 Mechanistic Biomarker ( ICOS high CD4 T cells) Company to Host Investor Event and Live Webcast on Tuesday, April 2, 2019 CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. Wed, 27 Feb 2019 16:35:00 -0500 Jounce Therapeutics, Inc. News Releases 7306 Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014 http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-completed-enrollment-first-cohort-phase-1 Dose Escalation Trial in Patients with Solid Tumors CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the Thu, 03 Jan 2019 08:00:00 -0500 Jounce Therapeutics, Inc. News Releases 7206 Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference http://ir.jouncetx.com/news-releases/news-release-details/jounce-therapeutics-present-37th-annual-jp-morgan-healthcare CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray , Ph.D., chief Wed, 02 Jan 2019 08:00:00 -0500 Jounce Therapeutics, Inc. News Releases 7211